Recent Updates
Recently added Catalysts
SPRO

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

Thursday, November 7, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Spero Therapeutics has announced it will release its financial results for the third quarter of 2024 on November 14, 2024, after market hours. The company, which specializes in developing treatments for rare diseases and multi-drug resistant infections, will not host a conference call following the announcement. This update may provide insights into Spero's ongoing projects and financial health.
Price reaction · baseline $1.31 (2024-11-06 close) · hit after-hours · clean, no other SPRO news in the window
day 0 close
0%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
7.4%
average across 5 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
Tebipenem pivoxil hydrobromide
Phase 1 · Renal Impairment

Full Press Release Details

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2024 financial results and provide an update on its business on Thursday, November 14, after the market close. The Company does not intend to host a conference call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information - www.sperotherapeutics.com
Investor Relations Contact:

Frequently Asked Questions

When will Spero Therapeutics report Q3 2024 financial results?

Spero Therapeutics will report its Q3 2024 financial results on November 14.

Will Spero host a conference call after their Q3 report?

No, Spero Therapeutics does not plan to hold a conference call.

What is the focus of Spero Therapeutics?

Spero Therapeutics focuses on treatments for rare diseases and MDR bacterial infections.

Where is Spero Therapeutics located?

Spero Therapeutics is headquartered in Cambridge, Massachusetts.

How can I contact Spero's investor relations?

You can contact Spero's investor relations at IR@Sperotherapeutics.com.

ShareAdd on Google
Tags: SPRO Viatris Investor Conferences Healthcare Spero Therapeutics financial results Q3 2024 biopharmaceuticals
Last updated: Nov 7, 2024

Biotech snapshot

Cash runway
$51M liquidity · $2M/mo burn
~28 mo
Minimal dilution risk
Lead asset
Tebipenem pivoxil hydrobromidePhase 1
Renal Impairment →

Catalyst track record

+8%
best trade around SPRO's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for SPRO.

See every catalyst's timing & PoA →